Loading…
Cardea Bio (formerly Nanomedical Diagnostics) has finalized its merger-acquisition of Nanosens Innovations, the creators of CRISPR-Chip technology. The deal combines Cardea's graphene biosensor infrastructure with Nanosens' CRISPR-Chip technology to develop DNA-based products.